Boenning & Scattergood’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Boenning & Scattergood’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,000	Closed	-$76K	–	310
2019 Q3	$76K	Sell	20,000 -2,500	-11%	-$9K	0.02%	265
2019 Q2	$149K	Sell	22,500 -12,400	-36%	-$47.2K	0.04%	267
2019 Q1	$124K	Hold	34,900	–	–	0.04%	276
2018 Q4	$138K	Buy	34,900 +25,350	+265%	+$324K	0.05%	256
2018 Q3	$189K	Buy	9,550 +4,800	+101%	+$121K	0.06%	263
2018 Q2	$151K	Buy	+4,750	New	+$171K	0.05%	266

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Boenning & Scattergood's MLNT Position: Q4 2019 in Review

Boenning & Scattergood sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 20,000 shares — an estimated $76K sold.

Boenning & Scattergood first reported a position in MLNT in Q2 2018 and held it in 6 quarters. The position peaked at $189K in Q3 2018. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Boenning & Scattergood reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Boenning & Scattergood sold 20,000 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $76K.
Boenning & Scattergood first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Boenning & Scattergood's Melinta Therapeutics, Inc. Common Stock position peaked at $189K in Q3 2018.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Boenning & Scattergood's 13F filing for Q4 2019, filed 15 Jan 2020.